Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Virchows Arch ; 465(2): 199-205, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24878757

RESUMO

We present the clinicopathological features of 56 cases of the nested variant of urothelial bladder carcinoma. This is an uncommon variant of bladder cancer, recognized by the current WHO classification of urologic tumors. The nested component represented 100 % of the tumor in 24 cases. The architectural pattern of the tumor varied from solid expansile to infiltrative nests characterized by deceptively bland histologic features resembling von Brunn nests. Typical features of high-grade conventional urothelial carcinoma were present in 32 cases. Most neoplastic cells had nuclei of low to intermediate nuclear grade with occasional nuclear enlargement, most frequently seen in deep areas of tumor. The nested component expressed cytokeratins 7, 20, CAM5.2, and high molecular weight (34ßE12), p63, Ki67, p53, p27, and GATA3. Tumor extension was T1 (n = 9), minimally T2 (n = 10), T2a (n = 1), T2b (n = 4), T3a (n = 8), T3b (n = 13), and T4a (n = 11). On follow-up, 36 of patients died of or were alive with disease from 2 to 80 months (mean 21 months). Four patients died of other causes. Eleven other patients remained disease free. Univariate survival analysis showed no differences for nested carcinoma compared with conventional urothelial carcinoma. As in conventional urothelial carcinoma, in nested carcinoma of the bladder pT category defined different survival groups. In summary, nested variant of urothelial bladder carcinoma is typically associated with advanced stage. In samples of limited volume, it may be misdiagnosed as proliferation of von Brunn nests or other nested-like bladder lesions, delaying definitive therapy.


Assuntos
Carcinoma de Células de Transição/mortalidade , Carcinoma de Células de Transição/patologia , Neoplasias da Bexiga Urinária/mortalidade , Neoplasias da Bexiga Urinária/patologia , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Células de Transição/metabolismo , Proliferação de Células , Feminino , Seguimentos , Fator de Transcrição GATA3/metabolismo , Humanos , Estimativa de Kaplan-Meier , Queratinas/metabolismo , Masculino , Proteínas de Membrana/metabolismo , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Taxa de Sobrevida , Proteína Supressora de Tumor p53/metabolismo , Neoplasias da Bexiga Urinária/metabolismo
2.
Am J Clin Pathol ; 141(5): 747-52, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24713751

RESUMO

OBJECTIVES: To investigate primary osteosarcoma (osteogenic sarcoma) of the kidney, a rare and aggressive neoplasm. METHODS: We present clinical and pathologic features of three female patients, aged 50, 66, and 78 years, affected by primary osteosarcoma of the kidney. The diagnosis was made by H&E-stained samples from totally (cases 1 and 2) or partially (case 3) embedded tumors. RESULTS: Reported cases showed histologic features of low-grade (n = 1), chondroblastic (n = 1), and osteoblastic (n = 1) osteosarcoma. Tumor size ranged from 3 to 7 cm, and pT category was pT1a (n = 1), pT1b (n = 1), and pT3a (n = 1). Immunohistochemistry gave focal positive results with PAX2 and CD10 in case 1 and S100 in case 2. On follow-up, two patients were disease free at 25 and 68 months and one died of metastases. CONCLUSIONS: Surgically treated primary renal osteosarcoma might not be as aggressive as previously thought if diagnosed early with low pT status.


Assuntos
Neoplasias Renais/patologia , Osteossarcoma/patologia , Idoso , Feminino , Humanos , Imuno-Histoquímica/métodos , Neoplasias Renais/diagnóstico , Neoplasias Renais/terapia , Pessoa de Meia-Idade , Gradação de Tumores , Osteossarcoma/diagnóstico , Osteossarcoma/terapia , Resultado do Tratamento
3.
Anal Quant Cytopathol Histpathol ; 35(3): 121-9, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24344498

RESUMO

The 2004 World Health Organization classification system for urothelial neoplasia identifies urothelial dysplasia (low-grade intraurothelial neoplasia) as a premalignant lesion of the urothelium. Although diagnostic criteria of urothelial dysplasia have been improved in recent years, there is a frequent lack of interobserver reproducibility. Follow-up studies suggest that dysplasia is a marker for urothelial instability and disease progression in up to 19% of patients, thus supporting an active clinical follow-up in these patients. The main differential diagnosis of urothelial dysplasia includes flat urothelial lesions with atypia, mainly flat (simple) urothelial hyperplasia, reactive urothelial atypia, urothelial atypia of unknown significance, and urothelial carcinoma in situ (high-grade intraurothelial neoplasia). In most cases, morphologic features alone suffice for diagnosis. Some cases may require a panel of immunohistochemical antibodies consisting of cytokeratin 20, p53 and CD44 for diagnosis. We present pathologic features and clinical significance of urothelial dysplasia with emphasis on differential diagnosis from common flat urothelial lesions with atypia.


Assuntos
Carcinoma in Situ/patologia , Neoplasias da Bexiga Urinária/patologia , Bexiga Urinária/patologia , Neoplasias Urológicas/patologia , Urotélio/patologia , Carcinoma in Situ/diagnóstico , Carcinoma Papilar/patologia , Diagnóstico Diferencial , Progressão da Doença , Humanos , Hiperplasia/patologia , Gradação de Tumores , Proteína Supressora de Tumor p53/genética , Neoplasias da Bexiga Urinária/diagnóstico , Neoplasias da Bexiga Urinária/genética , Neoplasias Urológicas/diagnóstico , Neoplasias Urológicas/genética
4.
Arch Esp Urol ; 66(5): 416-22, 2013 Jun.
Artigo em Espanhol | MEDLINE | ID: mdl-23793759

RESUMO

OBJECTIVES: The advances in cancer translational research, as well as the study of its changes and interactions, depend basically on the procurement of case series (individuals affected and non affected controls) which supply high quality samples and other associated data. Biobanks have shown they are indispensable tools for the advance of uro-oncological research. METHODS: Bibliographic review based on biobanks with focus on Urology. RESULTS AND CONCLUSIONS: Well-organized, large biobanks are a key element in research in Uro-oncology. The integration of theses resources with molecular sciences and various "omics", together with powerful available bioinformatic tools enable the advance in the knowledge of development of uro-oncological diseases, with strong implications at the time of very advanced therapeutic strategies. However,in Spain, these valuable collections of tissue material and biological fluids are usually not much in use, mainly due to fragmentation, low accessibility, lack of proper management strategies (such as lack of consensus about standard operative procedures), limited specific policies of use and distribution, as well as lack of a comprehensive base in which the research needs are reflected under interdisciplinar and multi-institutional focus. We must add the frequent ignorance of the high scientific potential of these institutions in the urological world. The development of the Spanish National Plan of Biobanks brings light for the better use of these materials by the uro-oncological community. We present a general view on the biobank topic, which may serve as a model for future debates about their use in uro-oncology. This approach is based in data from the literature and results of discussions in various international forums.


Assuntos
Oncologia/organização & administração , Neoplasias Urológicas/patologia , Urologia/organização & administração , Animais , Bancos de Espécimes Biológicos/organização & administração , Bancos de Espécimes Biológicos/normas , Humanos , Oncologia/normas , Pesquisa Translacional Biomédica , Neoplasias Urológicas/genética
5.
Anal Quant Cytopathol Histpathol ; 35(2): 61-76, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23700715

RESUMO

The use of classic and newer methodologies, including histopathology, electron microscopy, immunohistochemistry, cytogenetics, and molecular diagnostic techniques, has greatly influenced distinctions between various types of renal carcinoma. The most recent World Health Organization classification of renal neoplasms encompassed nearly 50 distinctive renal neoplasms. These categories have been expanded during recent years, incorporating newer histotypes, thus suggesting that the next revision of this classification will incorporate some of the recently recognized entities. In this review we examine the clinicopathologic and genetic features of renal carcinomas most often seen in clinical practice. Emphasis is placed on defining risk categories by incorporating pathologic predictive paradmeters and tumor histotypes. Since pathology of renal cell cancer is a rapidly evolving field, we also include brief comments on newer tumor variants for which there currently is not enough clinicopathologic information to permit classification as distinctive tumor histotypes.


Assuntos
Carcinoma de Células Renais/classificação , Carcinoma de Células Renais/patologia , Neoplasias Renais/classificação , Neoplasias Renais/patologia , Organização Mundial da Saúde , Carcinoma de Células Renais/genética , Humanos , Neoplasias Renais/genética , Prognóstico
6.
BJU Int ; 110(11): 1775-80, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22462607

RESUMO

UNLABELLED: Study Type--Pathology (case series) Level of Evidence 4. What's known on the subject? and What does the study add? Lymphocytic vasculitis of the prostate is an exceedingly rare form of localised vasculitis that presents without systemic involvement, and is illustrated with anecdotal case reports; often as localised polyarteritis nodosa-like vasculitis. True incidence and clinical significance of lymphocytic vasculitis of the prostate in surgical specimens is virtually unknown. The present findings support that lymphocytic vasculitis of the prostate was present in 67 (12.4%) of 540 specimens. Lymphocytic vasculitis of the prostate was present in 14 (93.3%) of 15 specimens with prostatic infarction (P < 0.001) with a risk of 124.68 (OR [odds ratio]; 95% CI [confidence interval] 16.07-967.07) as compared with BPH cases not associated with lymphocytic vasculitis. OBJECTIVE: • To present our experience of lymphocytic vasculitis of the prostate in men with benign prostatic hyperplasia (BPH) without systemic involvement, as this is an exceedingly rare form of localised vasculitis and the incidence in surgical specimens and clinical significance of lymphocytic vasculitis is virtually unknown. PATIENTS AND METHODS: • A sequential cohort series of 540 surgical specimens removed because of BPH-related symptoms, including simple prostatectomy (374 men) and transurethral resection of the prostate (166), comprised the study group. • All men had histological diagnosis of BPH and received surgical therapy only. None of the men had had previous surgery or granulomatous prostatitis. • The mean (range) age at diagnosis was 67.8 (38-89) years. RESULTS: • Lymphocytic vasculitis of the prostate was present in 67 (12.4 %) of 540 specimens. It was seen in a variable number of small- to medium-sized parenchyma arteries with segmental to transmural lymphocytic inflammation, within the morphological spectrum of a polyarteritis nodosa (PAN)-like lesion seen at the periphery of BPH nodules. • In four cases, focal fibrinoid necrosis was seen in vessels with otherwise typical lymphocytic vasculitis features. Immunohistochemical staining showed a T cell predominant polymorphic cellular infiltrate with a minor component of B cells and monocytes. Six cases additionally had eosinophils (<1% of inflammatory cells). • Lymphocytic vasculitis of the prostate was present in 14 (93.3%) of 15 specimens with prostatic infarction (P < 0.001) with a risk of 124.68 (odds ratio [OR]; 95% confidence interval [CI] 16.07-967.07) as compared with BPH cases not associated with lymphocytic vasculitis. Logistic regression multivariate analysis selected both lymphocytic vasculitis of the prostate and patient age as significant predictors of prostate infarction with lymphocytic vasculitis being the most significant (P < 0.001; OR 128.12; 95% CI 16.298-1007.202). Follow-up information was available in all cases, range 2-16 years, and none of the patients developed systemic disease. • A validation set of 1665 additional cases including radical prostatectomy, cystoprostatectomy, and needle biopsies showed lymphocytic vasculitis of the prostate being associated to prostate infarction on univariate and multivariate logistic regression (P < 0.001; OR 228.34; 95% CI 45.17-1154.22) analyses. CONCLUSIONS: • Lymphocytic vasculitis in men with BPH is associated with prostatic infarction and should be considered a form of localised vasculitis with PAN-like morphology that does not necessitate additional evaluation for systemic disease. • The potential clinical relevance of lymphocytic vasculitis warrants further investigation.


Assuntos
Doenças Linfáticas/complicações , Próstata/irrigação sanguínea , Hiperplasia Prostática/complicações , Vasculite/complicações , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/metabolismo , Humanos , Infarto/etiologia , Infarto/patologia , Doenças Linfáticas/patologia , Masculino , Pessoa de Meia-Idade , Hiperplasia Prostática/patologia , Vasculite/patologia
7.
Gastroenterol Hepatol ; 30(1): 22-4, 2007 Jan.
Artigo em Espanhol | MEDLINE | ID: mdl-17266878

RESUMO

Gastrointestinal stromal tumors (GIST) are an infrequent cause (<1%) of severe gastrointestinal hemorrhage. Treatment is mainly surgical through complete tumoral resection. We report the case of a 29-year-old woman who presented to the emergency room with severe gastrointestinal bleeding manifested by melena. On physical examination the patient had a painless, palpable mass in the left abdomen. Esophagogastroduodenoscopy, computed tomography, angiography and urgent surgical intervention led to diagnosis of a jejunal GIST.


Assuntos
Hemorragia Gastrointestinal/etiologia , Tumores do Estroma Gastrointestinal/complicações , Neoplasias do Jejuno/complicações , Adulto , Feminino , Humanos , Índice de Gravidade de Doença
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA